SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Virax Biolabs Group Limited (VRAX) has a negative trailing P/E of -0.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -821.12%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+567.6%).
- Trailing Earnings Yield -821.12% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $1.00 (+567.6% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VRAX
Valuation Multiples
P/E (TTM)-0.1
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.13
P/S Ratio209.83
EV/EBITDA0.4
Per Share Data
EPS (TTM)$-1.18
Book Value / Share$1.07
Revenue / Share$0.00
FCF / Share$-1.27
Yields & Fair Value
Earnings Yield-821.12%
Dividend Yield0.00%
Analyst Target$1.00 (+567.6%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-258.4 |
0.00 |
-196.01 |
2,072.65 |
- |
| 2021 |
-318.0 |
17.12 |
-347.22 |
1,671.85 |
- |
| 2022 |
-121.1 |
-0.74 |
-212.41 |
0.00 |
- |
| 2023 |
-1.4 |
-0.01 |
0.81 |
863.45 |
- |
| 2024 |
-0.2 |
0.01 |
0.27 |
9.43 |
- |
| 2025 |
-0.6 |
0.01 |
0.62 |
557.69 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-0.70 |
$99.88K |
$-801.13K |
-802.1% |
| 2021 |
$-0.57 |
$123.82K |
$-650.98K |
-525.8% |
| 2022 |
$-1.50 |
$0.00 |
$-1.71M |
- |
| 2023 |
$-5.13 |
$8.56K |
$-5.46M |
-63748.3% |
| 2024 |
$-3.36 |
$156.42K |
$-6.73M |
-4304.8% |
| 2025 |
$-1.95 |
$6.33K |
$-6.06M |
-95739.2% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.40 |
$-0.40 – $-0.40 |
$40K |
$40K – $40K |
1 |
| 2027 |
$-0.24 |
$-0.24 – $-0.24 |
$4K |
$4K – $4K |
1 |
